Faculty, Staff and Student Publications

Publication Date

8-4-2025

Journal

Cancer Discovery

DOI

10.1158/2159-8290.CD-24-1390

PMID

40249124

PMCID

40249124

PubMedCentral® Posted Date

8-4-2025

PubMedCentral® Full Text Version

Post-print

Abstract

In a phase II trial, patients with local-regionally advanced human papillomavirus-positive oropharyngeal carcinoma (n = 35) received ipilimumab (anti-CTLA4) and nivolumab (anti-PD-1) as induction immunotherapy and concurrently with radiotherapy (NCT03799445). Coprimary endpoints included 6-month complete metabolic response rate (94%) and 2-year progression-free survival (84%). Induction yielded a 46% major histopathologic response rate. Single-cell profiling revealed responders had higher baseline intratumoral CD8+ T cells with a tumor-reactive, tissue-resident memory (TRM) phenotype and a treatment-related decrease in effector regulatory T (eTreg) cells. The eTreg decrease correlated with CD8+ T-cell clonotype transitioning from TRM to effector memory and IFNG+ effector cells. In nonresponders, clonotypes transitioned to exhausted TRM and proliferating cells. Multivariable regression modeling determined that the baseline feature most associated with reduction in tumor viability was the proportion of FCGR3A-expressing NK cells, which are capable of ipilimumab-dependent depletion of CTLA4high eTregs. eTreg depletion may be critical for major response to induction dual immune checkpoint blockade (ICB).

Significance: The relative contributions of CD28 costimulation restoration versus Treg depletion to clinical response to CTLA4 ICB is a matter of considerable controversy. In this study, we provide compelling data that eTreg depletion is critical to tumor clearance in patients treated with dual PD-1 and CTLA4 ICB.

Keywords

Humans, T-Lymphocytes, Regulatory, Immune Checkpoint Inhibitors, Female, Male, Ipilimumab, Middle Aged, Aged, Oropharyngeal Neoplasms, Nivolumab

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.